OraSure Technologies, Inc. — FY2022 Form 10-K
Business context and reporting period. This annual filing covers the fiscal year ended December 31, 2022; it is not a standalone fourth-quarter report. OraSure develops and sells rapid diagnostic tests, specimen-collection products, and molecular laboratory and analytical services. Its two reporting segments were Diagnostics and Molecular Solutions. In February 2023, the company announced plans to combine their commercial and innovation teams and report on a non-segmented basis starting in Q1 2023.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net revenue | $387.5 million | $233.7 million |
| Gross profit / margin | $147.6 million / 38% | $117.6 million / 50% |
| Operating loss | $23.0 million | $10.2 million |
| Net loss | $17.9 million; $0.25 per diluted share | $23.0 million; $0.32 per diluted share |
| Cash used in operating activities | $47.2 million | $35.4 million |
| Cash, cash equivalents and available-for-sale securities at year-end | $110.8 million | $170.0 million |
| Working capital at year-end | $255.3 million | $231.2 million |
| Total assets / liabilities at year-end | $444.7 million / $81.1 million | $461.0 million / $80.5 million |
The filing reports no conventional borrowings in the supplied balance-sheet information. Lease liabilities totaled approximately $12.5 million at year-end 2022, including operating and finance leases.
Material changes versus FY2021
- Revenue rose 66%, principally because InteliSwab COVID-19 rapid-test revenue increased to $233.7 million from $22.7 million. Diagnostics segment revenue was $303.7 million, up 237%; Molecular Solutions revenue was $83.8 million, down 42%.
- Molecular Solutions declines included COVID-19 collection-kit revenue falling 82% to $9.7 million, genomics revenue down 14% to $54.3 million, and laboratory-services revenue down 38% to $7.3 million. Management cited lower PCR testing, customer inventory, changing customer priorities, and a laboratory-services customer ceasing operations.
- Gross margin fell to 38% from 50%, reflecting product mix and the loss of a $2.5 million Employee Retention Credit benefit included in 2021 gross profit.
- Operating loss widened despite higher sales, with $17.1 million of impairment charges in 2022 and increased operating expenses. Net loss narrowed partly because 2021 included substantially higher income-tax expense.
- Operating cash use increased to $47.2 million. Inventory rose $43.0 million and accounts receivable rose $25.2 million, principally reflecting inventory built for expected COVID-19 demand and late-year shipments.
Outlook, commentary, risks and unusual items
- COVID-19 outlook: Management anticipated higher InteliSwab revenue in the first half of 2023 and lower revenue in the second half as government contracts are worked down. It cautioned that demand may decline or fluctuate with the prevalence of COVID-19 and that future demand is uncertain.
- Government contracts: A second DLA contract estimated 18 million tests, with a 36 million maximum and 3.6 million guaranteed minimum, running through November 2023. HHS separately awarded a fully funded contract for 3.2 million tests delivered in February 2023. A $109 million DOD/HHS agreement funds expanded U.S. manufacturing capacity; $60.3 million had been received, with $48.7 million expected within the next year. Funding depends on milestones and timing.
- Concentration and liquidity: One customer accounted for approximately 58% of FY2022 revenue and more than 57% of year-end receivables. Approximately $71.0 million, or 64%, of cash and available-for-sale securities was held by the Canadian subsidiary; further repatriation could result in additional tax costs. Management said available balances should fund current and foreseeable needs.
- Inventory and impairments: Inventory reached $96.2 million, up from $53.1 million; inventory valuation depends on demand forecasts and expiration-date assumptions. The company recorded $8.6 million of Molecular Solutions manufacturing-asset impairments, $4.9 million of Diagnostics manufacturing-asset impairments, and a $3.6 million Diagnostics goodwill impairment.
- Restructuring and leadership: The company announced an 11% reduction in its non-production workforce in February 2023, with most related expense expected in Q1 2023. It also announced a reorganization intended to improve innovation, customer experience, and operating synergies. CEO and senior-leadership transitions occurred during 2022.
- Other risks and contingencies: The filing highlights competitive, regulatory and EUA-related risks; manufacturing scale-up and sole-source supply risks; foreign-exchange exposure; and dependence on public funding. Patent litigation with Spectrum Solutions remained pending, including a summary-judgment motion and review of a patent by the Patent and Trademark Office. Management did not expect ordinary-course legal matters to materially affect results. The filing reports an unqualified audit opinion and effective internal control over financial reporting; a material weakness in IT user-access controls identified during 2022 was remediated, with no resulting misstatement.
Most important facts for investors to verify
- Whether the highly concentrated customer continues ordering at a level consistent with 2022 and whether related receivables are collected.
- Actual 2023 InteliSwab sales, government delivery orders, minimum contract quantities, and timing of DOD milestone reimbursements.
- Inventory turnover, expiration exposure, and the adequacy of inventory reserves as COVID-19 demand changes.
- Whether cash burn and gross margins improve as COVID-19 revenue moderates, and whether restructuring delivers expected savings.
- The amount and tax consequences of any further Canadian cash repatriation, and the outcome and potential costs of the Spectrum patent litigation.